Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

645
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
645
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.3K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

151
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
151
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

117
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
117
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

66
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
66

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osimertinib-induced cardiotoxicity is driven by HDAC-dependent epigenetic repression and rescued by vorinostat.

Signal transduction and targeted therapy·2026
Same author

Myeloid-derived immunosuppressive PD-1/PD-L1 signaling is essential to maintain adult heart homeostasis.

American journal of physiology. Heart and circulatory physiology·2026
Same author

Small extracellular vesicle signaling and mitochondrial transfer reprogram T helper cell function in human asthma.

Nature communications·2026
Same author

Cardiomyocytes HIPK2 regulates myocardial inflammation and heart function through purinergic signaling.

Cell communication and signaling : CCS·2026
Same author

Correction to: Novel Mechanisms of Exosome-Mediated Phagocytosis of Dead Cells in Injured Heart.

Circulation research·2026
Same author

Transmitophagy in the heart: An overview of molecular mechanisms and implications for pathophysiology.

Acta pharmaceutica Sinica. B·2026
Same journal

Systematic Review of Antifibrotic Effects of Metformin: Insights from Preclinical and Clinical Studies and Potential Relevance to Oral Submucous Fibrosis.

Pharmacological research·2026
Same journal

Loss of ETV4 triggers PPM1E downregulation and AMPK-ULK1-dependent autophagy to promote intrinsic trametinib resistance in breast cancer.

Pharmacological research·2026
Same journal

Editorial: Current pharmacological challenges of Treatment-Resistant Depression.

Pharmacological research·2026
Same journal

GLP-1 Receptor Agonist Therapy in Children and Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles.

Pharmacological research·2026
Same journal

Sinomenine regulates the AKT/FOXO3/GLUL pathway to inhibit pulmonary fibroblast-to-myofibroblast transition via α7nAChR against rheumatoid arthritis associated interstitial lung disease.

Pharmacological research·2026
Same journal

Ketohexokinase: A central mediator of fructose-associated pathogenesis and promising therapeutic target.

Pharmacological research·2026
See all related articles

Related Experiment Video

Updated: Nov 6, 2025

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.3K

Repurposing Nintedanib for pathological cardiac remodeling and dysfunction.

Prachi Umbarkar1, Anand P Singh1, Sultan Tousif1

  • 1Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, AL 35294-1913, USA.

Pharmacological Research
|May 9, 2021
PubMed
Summary
This summary is machine-generated.

Nintedanib (NTB) effectively treats cardiac fibrosis and dysfunction in mice with heart failure. Its benefits persist even after treatment cessation, suggesting a potential new therapy for heart disease.

Keywords:
FibrosisHeart failureInflammation

More Related Videos

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.4K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.5K

Related Experiment Videos

Last Updated: Nov 6, 2025

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.3K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.4K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.5K

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Fibrosis Research

Background:

  • Heart failure (HF) is a leading global cause of death, often driven by myocardial fibrosis.
  • Current treatments lack specific agents targeting cardiac fibrosis.
  • Nintedanib (NTB), an FDA-approved drug for lung fibrosis, shows promise for cardiac applications.

Purpose of the Study:

  • To investigate the efficacy and safety of Nintedanib (NTB) in treating cardiac fibrosis and dysfunction.
  • To explore the underlying mechanisms of NTB's cardioprotective effects in a murine model of HF.

Main Methods:

  • A murine model of HF was established using Transverse Aortic Constriction (TAC).
  • Mice received Nintedanib (NTB) orally, with cardiac function assessed via echocardiography.
  • Histological, morphometric, and molecular analyses were performed to evaluate fibrosis, inflammation, and cellular changes.

Main Results:

  • NTB treatment significantly prevented TAC-induced cardiac functional decline and reduced myocardial fibrosis.
  • Beneficial effects on cardiac function were maintained even after NTB treatment interruption.
  • NTB modulated inflammatory responses, reduced cardiomyocyte size, and inhibited pro-fibrotic pathways in vitro.

Conclusions:

  • Nintedanib (NTB) demonstrates significant therapeutic potential for combating cardiac fibrosis and HF.
  • The drug's protective effects extend beyond fibrosis, influencing inflammation and cellular signaling.
  • Findings support repurposing NTB for HF treatment, warranting further investigation in advanced models and clinical trials.